Please try another search
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.
Name | Age | Since | Title |
---|---|---|---|
Henry Chen | - | 2024 | Director |
Nan Zhang | - | 2024 | CEO & Director |
Pierson Yue Pan | - | 2024 | Director |
Haitao Zhao | - | 2024 | Director |
Chunyuan Wu | 45 | 2024 | Chief Financial Officer & Director |
Hui Shao | 56 | 2023 | President, CEO & Executive Director |
Viren Mehta | 74 | 2023 | Independent Director |
Ajit S. Shetty | 77 | 2023 | Independent Chairman |
Rui Yu | 49 | 2023 | Independent Director |
Jin Wang | - | 2024 | Independent Director |
Yuntao Cui | - | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review